UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential

Maxim Group initiated coverage on Threshold Pharmaceuticals THLD with a Buy rating and a price target of $10 per share. Maxim Group commented, "THLD's lead drug, TH-302, is currently in a phase III trial as a first-line treatment with doxorubicin for advanced soft tissue sarcoma (STS) and at the end of a phase IIb trial as a first-line therapy with gemcitabine for pancreatic cancer. Both cancers are difficult-to-treat malignancies with limited chemotherapies on the market. Based on earlier trial results, we believe there is a good chance for THLD to deliver significant improvement of overall survival (OS) in expanded patient populations." Threshold Pharmaceuticals closed at $7.78 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationIntraday UpdateAnalyst RatingsMaxim Group
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!